Pierre J.M.B. Raboisson
EVP, Head of Small Molecule Medicinal Chemistry, Head of Belgium Site (Leuven) at Aligos Therapeutics
Pierre J.M.B. Raboisson, Pharm.D. Ph.D., has served as the European Site Head in Leuven, Belgium, and Head of small molecule Medicinal Chemistry since September 2018. Dr. Raboisson has over 20 years of experience in medicinal chemistry and drug discovery of small molecules. Prior to establishing the European site and delivering a number of drug candidates for Aligos Therapeutics, Dr Raboisson was Vice President and Research Fellow of Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, where he was the Global European Head of Medicinal Chemistry from June 2018 to September 2018, having responsibilities across four therapeutic areas: Infectious Diseases, Oncology, Neuroscience and Global Public Health. From September 2016-September 2018, Dr Raboisson served as Vice President and Head of European Research for the Infectious Diseases Therapeutic area of Janssen Pharmaceutical Companies of Johnson & Johnson. From March 2004-September 2016, Dr Raboisson had increasing responsibilities at Tibotec Therapeutics, which became Janssen Therapeutics, Division of Janssen Products, LP in June 22, 2011. Dr. Raboisson received his Pharmacist Degree and Ph.D. in Medicinal Chemistry from the University Louis Pasteur from Strasbourg, France and had his post-doctoral training at ArQule Inc, Woburn. We believe that Raboisson’s extensive experience in small molecule research and development, his managerial skills and his educational background provides him with the qualifications and skills necessary to serve as a European Site Head, Head of Small Molecule Medicinal Chemistry and member of our Senior Leadership Team.
EVP, Head of Small Molecule Medicinal Chemistry, Head of Belgium Site (Leuven)
VP, Head of Small Molecule Medicinal Chemistry, Head of Belgium Site (Leuven)